Patient characteristics
| Diagnosis . | Age, y . | Sex . | IFN, mo . | Medical history . | Imatinib, d . | Starting dose, mg/d . | Imatinib after event . | Comments . | Echo/MUGA, %M . | |
|---|---|---|---|---|---|---|---|---|---|---|
| Before . | After . | |||||||||
| CML | 66 | M | 15 | NIDDM, HTN | 893 | 400 | Discontinued due to progression | Iron overload | NA | NA |
| CML | 75 | M | 7 | CHF, IDDM, MI | 801 | 400 | Discontinued due to progression | — | NA | MUGA, 26 |
| CML | 73 | M | 2 | MI | 695 | 400 | Continued, same dose | CHF after pacemaker placement | NA | 40 |
| CML | 50 | F | 2* | CHF, IDDM | 283 | 400 | Continued, same dose | — | NA | 25-30 |
| CML | 83 | M | 0 | HTN, CAD | 1525 | 800 | Continued, same dose | — | NA | NA |
| CML | 68 | M | 0 | HTN, MI, CAD | 171 | 600 | Discontinued for CHF | — | 45-50 | 25-30 |
| CML AP | 76 | F | 0 | — | 414 | 600 | Continued, dose reduced to 400 mg daily | Found to have afib; CHF resolved with correction of afib | NA | MUGA, 76 |
| CML AP | 55 | F | 0 | HTN, MI | 98 | 600 | Continued, dose reduced to 400 mg daily | Admitted with CP; thallium revealed reversible ischemia | NA | 55 |
| CML AP | 65 | F | 19 | CHF, NIDDM, HTN, CAD, Arr | 153 | 600 | Death from sepsis | — | NA | 65-70 |
| PV | 74 | F | 0 | CHF, HTN | 32 | 400 | Discontinued for CHF | — | NA | NA |
| SMD | 75 | M | 0 | — | 293 | 300 | Continued same dose | NA | NA | |
| ET | 61 | F | 12 | — | 225 | 800 | Discontinued for CHF | Concomitant use of anagrelide | NA | 30-35 |
| MF | 77 | F | 0 | NIDDM | 67 | 400 | Discontinued for CHF | Hemglobin 83 g/L at event | 65 | NA |
| CML | 57 | F | 0 | NIDDM, HTN, Arr | 298 | 800 | Continued, dose reduced to 600 mg daily | Admitted with DOE had hemoglobin 60 g/L; resolved with correction of anemia | NA | NA |
| CML | 73 | F | 0 | Arr | 135 | 800 | Continued, dose reduced to 400 mg | — | 65 | Normal (outside) |
| CML | 58 | M | 76 | — | 1397 | 600 | Discontinued for CHF | VTach, ECHO showed 35% EF; CC not done because patient had progressive disease | NA | 20 |
| CML BP | 63 | F | 79 | CHF | 35 | 600 | Discontinued for CHF | Bilateral pneumonia with EF 40%; diagnosed with hypothyroidism, recovered with synthroid | 50-59 | 39 |
| CML | 57 | M | 7 | HTN | 87 | 400 | Continued same dose | Chest pain; CC revealed CAD with 16% EF; CAD thought not to explain cardiomyopathy | NA | 16 |
| CML | 57 | M | 24 | CAD | 2045 | 800 | Continued, dose reduced to 400 mg daily | — | NA | 60-65 |
| CML AP | 70 | M | 48 | CHF | 2 | 600 | Death | — | NA | NA |
| ALL | 75 | M | 0 | HTN | 43 | 400 | Continued same dose | Later died from sepsis | NA | 50 |
| CML BP | 81 | M | 3 | HTN, CAD | 1317 | 600 | Progression | CAD; disease progressing at the time of CHF with increasing dose from 200 to 600 mg/d; prior anthracyclines | NA | 25 |
| Diagnosis . | Age, y . | Sex . | IFN, mo . | Medical history . | Imatinib, d . | Starting dose, mg/d . | Imatinib after event . | Comments . | Echo/MUGA, %M . | |
|---|---|---|---|---|---|---|---|---|---|---|
| Before . | After . | |||||||||
| CML | 66 | M | 15 | NIDDM, HTN | 893 | 400 | Discontinued due to progression | Iron overload | NA | NA |
| CML | 75 | M | 7 | CHF, IDDM, MI | 801 | 400 | Discontinued due to progression | — | NA | MUGA, 26 |
| CML | 73 | M | 2 | MI | 695 | 400 | Continued, same dose | CHF after pacemaker placement | NA | 40 |
| CML | 50 | F | 2* | CHF, IDDM | 283 | 400 | Continued, same dose | — | NA | 25-30 |
| CML | 83 | M | 0 | HTN, CAD | 1525 | 800 | Continued, same dose | — | NA | NA |
| CML | 68 | M | 0 | HTN, MI, CAD | 171 | 600 | Discontinued for CHF | — | 45-50 | 25-30 |
| CML AP | 76 | F | 0 | — | 414 | 600 | Continued, dose reduced to 400 mg daily | Found to have afib; CHF resolved with correction of afib | NA | MUGA, 76 |
| CML AP | 55 | F | 0 | HTN, MI | 98 | 600 | Continued, dose reduced to 400 mg daily | Admitted with CP; thallium revealed reversible ischemia | NA | 55 |
| CML AP | 65 | F | 19 | CHF, NIDDM, HTN, CAD, Arr | 153 | 600 | Death from sepsis | — | NA | 65-70 |
| PV | 74 | F | 0 | CHF, HTN | 32 | 400 | Discontinued for CHF | — | NA | NA |
| SMD | 75 | M | 0 | — | 293 | 300 | Continued same dose | NA | NA | |
| ET | 61 | F | 12 | — | 225 | 800 | Discontinued for CHF | Concomitant use of anagrelide | NA | 30-35 |
| MF | 77 | F | 0 | NIDDM | 67 | 400 | Discontinued for CHF | Hemglobin 83 g/L at event | 65 | NA |
| CML | 57 | F | 0 | NIDDM, HTN, Arr | 298 | 800 | Continued, dose reduced to 600 mg daily | Admitted with DOE had hemoglobin 60 g/L; resolved with correction of anemia | NA | NA |
| CML | 73 | F | 0 | Arr | 135 | 800 | Continued, dose reduced to 400 mg | — | 65 | Normal (outside) |
| CML | 58 | M | 76 | — | 1397 | 600 | Discontinued for CHF | VTach, ECHO showed 35% EF; CC not done because patient had progressive disease | NA | 20 |
| CML BP | 63 | F | 79 | CHF | 35 | 600 | Discontinued for CHF | Bilateral pneumonia with EF 40%; diagnosed with hypothyroidism, recovered with synthroid | 50-59 | 39 |
| CML | 57 | M | 7 | HTN | 87 | 400 | Continued same dose | Chest pain; CC revealed CAD with 16% EF; CAD thought not to explain cardiomyopathy | NA | 16 |
| CML | 57 | M | 24 | CAD | 2045 | 800 | Continued, dose reduced to 400 mg daily | — | NA | 60-65 |
| CML AP | 70 | M | 48 | CHF | 2 | 600 | Death | — | NA | NA |
| ALL | 75 | M | 0 | HTN | 43 | 400 | Continued same dose | Later died from sepsis | NA | 50 |
| CML BP | 81 | M | 3 | HTN, CAD | 1317 | 600 | Progression | CAD; disease progressing at the time of CHF with increasing dose from 200 to 600 mg/d; prior anthracyclines | NA | 25 |
PV indicates polycythemia vera; ET, essential thrombocytosis; Mast, mastocytosis; HTN, hypertension; NIDDM, noninsulin diabetes mellitus; IDDM, insulin-dependent diabetes mellitus; Arr, arrthymia, afib, atrial fibrillation; EF, ejection fraction; CP, chest pain; CC, cardiac catheterization; and DOE, dyspnea on exertion; NA, not applicable; —, not available.
Just prior to event.